|
|
Anti-inflammatory effect of interleukin-35 in mice with colitis and its mechanism |
LU Zhanjun1,2,3( ),HU Yangyang2,3,LI Sisi2,3,ZANG Lijuan4,JIANG Weiliang2,3,WU Jianjiong2,WU Xiening2,ZENG Yue2,3,WANG Xingpeng1,2,3,*( ) |
1. Department of Gastroenterology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China 2. Department of Gastroenterology, Shanghai General Hospital, Shanghai 200080, China 3. Shanghai Key Laboratory of Pancreatic Disease, Shanghai 200080, China 4. Pathology Center, Shanghai General Hospital, Shanghai 200080, China |
|
|
Abstract Objective: To investigate the anti-inflammatory effect and mechanisms of interleukin-35 (IL-35) in inflammatory bowel disease. Methods: BALB/c mice were divided into three groups with 10 mice in each group:control group, model group (oral administration of 4% glucan sodium sulfate for 7 d) and IL-35-treated group (oral administration of 4% glucan sodium sulfate for 7 d, intraperitoneal injection of 2 μg IL-35 at d2-5). Disease activity index (DAI) was scored every day. After 7 d, the mice were sacrificed, and the serum and intestinal tissue samples were collected. The gross morphology of the colon was observed; HE staining was used to observe the pathological changes of colon tissue; flow cytometry was employed to detect the change of macrophage polarization ratio in colon tissue; the mRNA expression levels of cytokines IL-6, TNF-α, IFN-γ, IL-10 and SHIP1 in colon tissue were determined by real-time quantitative RT-PCR; the expression and distribution of SHIP1 in colon tissue was measured by immunohistochemistry; Western blotting was adopted to detect the expression level of SHIP1 protein in colonic intestinal tissues of each group. Results: The DAI scores of the mice in the model group were higher than those in the control group, while the DAI scores in the IL-35-treated group were lower than those in the model group (all P < 0.01). Compared with the control group, the colon length was significantly shortened in the model group (P < 0.05), while the colon length of the IL-35-treated group had an increasing trend compared with the model group, but the difference was not statistically significant (P > 0.05). Compared with the model group, microscopic inflammatory infiltration score was decreased and microscopic crypt destruction and score was significantly lower in IL-35-treated group (all P < 0.05). The relative expression of proinflammatory cytokines IL-6, TNF-α and IFN-γ in the colon tissue of IL-35-treated group was decreased compared with the model group, while the relative expression of IL-10 mRNA was higher than that of the model group (all P < 0.05). Compared with the control group, the proportion of M1 macrophages in the model group increased (P < 0.05), while the proportion of M1 macrophages in the IL-35-treated group was lower than that in the model group (P < 0.05). The relative expression of SHIP1 mRNA and protein in the colon tissue of IL-35-treated group was higher than that in the model group (all P < 0.05). Conclusion: IL-35 can inhibit the polarization of M1 macrophages and regulate inflammatory cytokines to promote anti-inflammatory effect on mice with colitis.
|
Received: 20 July 2018
Published: 23 January 2019
|
|
Corresponding Authors:
WANG Xingpeng
E-mail: lzjdoctor@126.com;richardwangxp@163.com
|
|
Cite this article:
LU Zhanjun,HU Yangyang,LI Sisi,ZANG Lijuan,JIANG Weiliang,WU Jianjiong,WU Xiening,ZENG Yue,WANG Xingpeng. Anti-inflammatory effect of interleukin-35 in mice with colitis and its mechanism. J Zhejiang Univ (Med Sci), 2018, 47(5): 499-506.
URL:
http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2018.10.09 OR http://www.zjujournals.com/med/Y2018/V47/I5/499
|
白介素35在炎性肠疾病中的抗炎作用机制
目的: 研究IL-35在炎性肠疾病中的抗炎作用及相关机制。方法: BALB/c雌性小鼠共30只,随机分为对照组、模型组(口服4%葡聚糖硫酸钠7 d)、IL-35组(口服4%葡聚糖硫酸钠7 d,第2~5天腹腔注射IL-35 2 μg/d),每组10只。每天对小鼠进行疾病活动指数(DAI)评分;7 d后处死小鼠,留取血清和肠道组织,观察结肠大体形态;HE染色观察各组结肠组织病理形态变化;流式细胞术检测各组结肠组织中巨噬细胞极化情况;实时定量RT-PCR检测各组结肠组织中细胞因子IL-6、TNF-α、γ干扰素(IFN-γ)、IL-10和Src同源系列2结构域的肌醇5-磷酸酶1(SHIP1)的mRNA表达量;免疫组织化学法检测各组结肠组织中SHIP1的表达及分布情况;蛋白质印迹法检测各组结肠组织中SHIP1蛋白的表达。结果: 模型组在实验过程中DAI评分较对照组增加,而IL-35组自第4天起DAI评分较模型组减少(均P < 0.01);与对照组比较,模型组结肠明显缩短(P < 0.05),而IL-35组的结肠长度长于模型组,但差异无统计学意义(P > 0.05);与模型组比较,IL-35组炎症细胞浸润减少、黏膜组织炎症评分和腺窝破坏组织评分较模型组减少(均P < 0.05);IL-35组结肠组织中促炎因子IL-6、TNF-α和IFN-γ的mRNA相对表达量较模型组减少,而抑炎因子IL-10的mRNA相对表达量较模型组增加(均P < 0.05);与对照组比较,模型组M1型巨噬细胞比例增加(P < 0.05),而IL-35组M1型巨噬细胞的比例较模型组减少(P < 0.05);IL-35组小鼠结肠组织中SHIP1 mRNA和蛋白相对表达量均较模型组增加(均P < 0.05)。结论: 在炎性肠疾病中,IL-35可以通过调控SHIP1表达抑制M1型巨噬细胞极化,以及调节炎症因子的表达发挥抗炎作用。
关键词:
炎性肠疾病/病理生理学,
白细胞介素类/代谢,
免疫组织化学,
印迹法, 蛋白质,
随机对照试验,
疾病模型, 动物
|
|
[1] |
KIM D H , CHEON J H . Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies[J]. Immune Netw, 2017, 17 (1): 25- 40
doi: 10.4110/in.2017.17.1.25
|
|
|
[2] |
POWELL N , LO J W , BIANCHERI P et al. Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation[J]. Gastroenterology, 2015, 149 (2): 456- 467
doi: 10.1053/j.gastro.2015.04.017
|
|
|
[3] |
CHOI J , LEUNG P S , BOWLUS C et al. IL-35 and autoimmunity:a comprehensive perspective[J]. Clin Rev Allergy Immunol, 2015, 49 (3): 327- 332
doi: 10.1007/s12016-015-8468-9
|
|
|
[4] |
LIU J Q , LIU Z , ZHANG X et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis[J]. J Immunol, 2012, 188 (7): 3099- 3106
doi: 10.4049/jimmunol.1100106
|
|
|
[5] |
FONSECA-CAMARILLO G , FURUZAWA-CARBALLEDA J , YAMAMOTO-FURUSHO J K . Interleukin 35(IL-35) and IL-37:intestinal and peripheral expression by T and B regulatory cells in patients with inflammatory bowel disease[J]. Cytokine, 2015, 75 (2): 389- 402
doi: 10.1016/j.cyto.2015.04.009
|
|
|
[6] |
OKAYASU I , HATAKEYAMA S , YAMADA M et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice[J]. Gastroenterology, 1990, 98 (3): 694- 702
doi: 10.1016/0016-5085(90)90290-H
|
|
|
[7] |
SCHEIFFELE F , FUSS I J . Induction of TNBS colitisin mice[J]. Curr Protoc Immunol, 2002,
|
|
|
[8] |
KMIE? Z , CYMAN M , ?LEBIODA T J . Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease[J]. Adv Med Sci, 2017, 62 (1): 1- 16
|
|
|
[9] |
QUETGLAS E G , MUJAGIC Z , WIGGE S et al. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease[J]. World J Gastroenterol, 2015, 21 (44): 12519- 12543
doi: 10.3748/wjg.v21.i44.12519
|
|
|
[10] |
LI Y , WANG Y , LIU Y et al. The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease[J]. Mediators Inflamm, 2014, 2014:136329
|
|
|
[11] |
SHEN P , ROCH T , LAMPROPOULOU V et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507 (7492): 366- 370
doi: 10.1038/nature12979
|
|
|
[12] |
PARK J S , JOE I , RHEE P D et al. A lactic acid bacterium isolated from kimchi ameliorates intestinal inflammation in DSS-induced colitis[J]. J Microbiol, 2017, 55 (4): 304- 310
doi: 10.1007/s12275-017-6447-y
|
|
|
[13] |
COLLISON L W , VIGNALI D A . Interleukin-35:odd one out or part of the family?[J]. Immunol Rev, 2008, 226:248- 262
doi: 10.1111/imr.2008.226.issue-1
|
|
|
[14] |
ZHANG J , LIN Y , LI C et al. IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis[J]. J Immunol, 2016, 197 (6): 2131- 2144
doi: 10.4049/jimmunol.1600446
|
|
|
[15] |
RUGTVEIT J , BRANDTZAEG P , HALSTENSENT S et al. Increased macrophage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35 (5): 669- 674
doi: 10.1136/gut.35.5.669
|
|
|
[16] |
ISIDRO R A , APPLEYARD C B . Colonic macrophage polarization in homeostasis, inflammation, and cancer[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 311 (1): G59- G73
doi: 10.1152/ajpgi.00123.2016
|
|
|
[17] |
LU Z J , WU J J , JIANG W L et al. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression[J]. World J Gastroenterol, 2017, 23 (6): 976- 985
doi: 10.3748/wjg.v23.i6.976
|
|
|
[18] |
KERR W G , PARK M Y , MAUBERT M et al. SHIP deficiency causes Crohn's disease-like ileitis[J]. Gut, 2011, 60 (2): 177- 188
doi: 10.1136/gut.2009.202283
|
|
|
[19] |
SLY L M , HO V , ANTIGNANO F et al. The role of SHIP in macrophages[J]. Front Biosci, 2007, 12:2836- 2848
doi: 10.2741/2276
|
|
|
[20] |
WEISSER S B , MCLARREN K W , VOGLMAIER N et al. Alternative activation of macrophages by IL-4 requires SHIP degradation[J]. Eur J Immunol, 2011, 41 (6): 1742- 1753
doi: 10.1002/eji.v41.6
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|